InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,477.90
(
0.16%
)
US TECH 100
19,129.60
(
-0.24%
)
Dow Jones
39,127.80
(
0.04%
)
Brent Oil
84.15
(
-0.38%
)
Bitcoin
61,039.16
(
0.37%
)
Post# of 252388
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 833
Posts 119931
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: linhdtu post# 226324

Thursday, 10/03/2019 6:45:16 PM

Thursday, October 03, 2019 6:45:16 PM

Post# of 252388
Re: (Non-nuke) HBV players

Other than ENTA, non-nuke HBV players include ABUS, who has an RNAi-based compound called AB-729 (#msg-149497836) that has a distinct MoA from the drug (AB-506) they just killed; ASBM (#msg-148213083); SBPH (#msg-148213028); and JNJ/ARWR, who are also pursuing an RNAi-based approach (#msg-150623753, #msg-143982835). None of these programs is in phase-3 yet, and all of the agents being tested will likely end up in a 2- or 3-drug combination.

I’m generally bearish on the RNAi-based approaches to HBV, including the two mentioned above.

p.s. There are several approved nukes for HBV (e.g. GILD’s Vemlidy) that suppress the virus but don’t eradicate it and hence are not cures.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up